Intravenous Ig Ameliorates Disease in a Murine Model of Anti–Laminin 332 Mucous Membrane Pemphigoid
Open Access
- 29 April 2024
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (12) , 2671-2681.e1
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Mucous membrane pemphigoidAutoimmunity Reviews, 2022
- Inhibition of Glucose Metabolism Abrogates the Effector Phase of Bullous Pemphigoid-Like Epidermolysis Bullosa AcquisitaJournal of Investigative Dermatology, 2021
- 12/15-Lipoxygenase choreographs the resolution of IgG-mediated skin inflammationJournal of Autoimmunity, 2020
- Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and ManagementClinical Reviews in Allergy & Immunology, 2017
- Experimental Laminin 332 Mucous Membrane Pemphigoid Critically Involves C5aR1 and Reflects Clinical and Immunopathological Characteristics of the Human DiseaseJournal of Investigative Dermatology, 2017
- The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa AcquisitaJournal of Investigative Dermatology, 2017
- Lipid-Cytokine-Chemokine Cascade Drives Neutrophil Recruitment in a Murine Model of Inflammatory ArthritisImmunity, 2010
- A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapiesClinical Immunology, 2004
- Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune Mucocutaneous Blistering DiseasesArchives of Dermatology, 2003
- The First International Consensus on Mucous Membrane PemphigoidArchives of Dermatology, 2002